Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

The study involves an experimental medicine trial carried out with healthy volunteers. It mirrors a previous trial undertaken with a similar group of participants. Both trials have investigated medications that are widely used to treat heart diseases, by lowering cholesterol and inflammation in the blood, atorvastatin and simvastatin. Whereas atorvastatin was linked to perceiving emotions as more negative, in contrast, simvastatin led to perceiving emotions as more positive. However, simvastatin was also seen to slightly increase subjective anxiety scores, perhaps mimicking what happens with commonly used antidepressants: an initial worsening of anxiety, later followed by an improvement in depressive and anxious symptoms.

Taken together, these findings suggest the possibility that atorvastatin might worsen depression and anxiety, while simvastatin might improve symptoms of depression, although at the expense of some increase in anxiety at the beginning of treatment.

In summary

Atorvastatin, used in the previous trial, is a highly potent statin that can reach the brain. Giving atorvastatin for seven days to healthy volunteers was associated with worse emotional perceptions, linked to later development of depressive and anxiety symptoms.

Simvastatin, used in the current trial, is a less strong statin, but it is also capable of entering the brain. Giving simvastatin for seven days to healthy volunteers was associated with a small improvement of emotional perceptions, which could in time lead to a reduction of depressive symptoms.


Dr Riccardo De Giorgi, study author and Wellcome Trust Doctoral Training Fellow, University of Oxford, said:


'Our findings are intriguing because they show that two similar medications, generally used to treat heart conditions, can not only affect the brain, but also do so in opposite ways. This provides some important insights about the effects of statins on common mental disorders, such as depression and anxiety. The ability of statins to reduce excessive inflammation could eventually lead to the development of better treatments. Further clinical studies, especially in patients currently suffering from depressive illness, are needed.'

Read the full study, An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in health volunteers, published in Psychopharmacology.


Similar stories

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

Many adolescents game a lot without negative effects on their wellbeing

Although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.